Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-01-31
2010-12-07
Aeder, Sean E (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100
Reexamination Certificate
active
07847070
ABSTRACT:
The invention provides the identification and characterization of disease and cancer-associated antigen, LUCA2. The invention also provides a family of monoclonal antibodies that bind to antigen LUCA2, methods of diagnosing and treating various human cancers and diseases that express LUCA2.
REFERENCES:
patent: 3842067 (1974-10-01), Sarantakis
patent: 3862925 (1975-01-01), Sarantakis et al.
patent: 3972859 (1976-08-01), Fujino et al.
patent: 4105603 (1978-08-01), Vale, Jr. et al.
patent: RE30548 (1981-03-01), Vale, Jr. et al.
patent: 4676980 (1987-06-01), Segal et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5552391 (1996-09-01), Coutts et al.
patent: 5565332 (1996-10-01), Hoogenboom et al.
patent: 5580717 (1996-12-01), Dower et al.
patent: 5656444 (1997-08-01), Webb et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5733743 (1998-03-01), Johnson et al.
patent: 5807715 (1998-09-01), Morrison et al.
patent: 5866692 (1999-02-01), Shitara et al.
patent: 5997867 (1999-12-01), Waldmann et al.
patent: 6054297 (2000-04-01), Carter et al.
patent: 6054561 (2000-04-01), Ring
patent: 6180377 (2001-01-01), Morgan et al.
patent: 6265150 (2001-07-01), Terstappen et al.
patent: 6331415 (2001-12-01), Cabilly et al.
patent: 6441163 (2002-08-01), Chari et al.
patent: 6682904 (2004-01-01), Frost
patent: 2004/0016006 (2004-01-01), Ji et al.
patent: 2004/0043029 (2004-03-01), Hellstrom et al.
patent: 0 519 596 (1992-12-01), None
patent: 0 519 596 (1992-12-01), None
patent: 1 473 301 (2004-11-01), None
patent: 1 473 301 (2004-11-01), None
patent: WO-01/43869 (2001-06-01), None
patent: WO-01/43869 (2001-06-01), None
patent: WO-04/001381 (2003-12-01), None
Harada et al (Tohoku J Exp Med, 1996, 180: 273-288).
Waibel et al (Cancer Research, Jun. 1993, 53:2840-2845).
Russell et al (BMJ 304:585-586, 1992).
International Search Report mailed Oct. 12, 2006, for PCT Application No. PCT/US06/03382 filed Jan. 31, 2006, three pages.
Kyoizumi, S. et al. (Jul. 1985). “Monoclonal Antibodies to Human Squamous Cell Carcinoma of the Lung and Their Application to Tumor Diagnosis,”Cancer Res. 45(7):3274-3281.
Aruffo, A. et al. (Dec. 1987). “Molecular Cloning of a CD28 cDNA by a High-Efficiency COS Cell Expression System,”Proc. Natl. Acad. Sci. USA84:8573-8577.
Bird, R.E. et al. (Oct. 21, 1988). “Single-Chain Antigen-Binding Proteins,”Science242:423-426.
Brown, B.A. et al. (Jul. 1, 1987). “Tumor-Specific Genetically Engineered Murine/Human Chimeric Monoclonal Antibody,”Cancer Res. 47:3577-3583.
Carter, P. et al. (May 1992). “Humanization of an Anti-p185HER2Antibody for Human Cancer Therapy,”Proc. Natl. Acad. Sci. USA89:4285-4289.
Co, M.S. et al. (Apr. 1991). “Humanized Antibodies for Antiviral Therapy,”Proc. Natl. Acad. Sci. USA88:2869-2873.
Co, M.S. et al. (Feb. 15, 1992). “Chimeric and Humanized Antibodies With Specificity for the CD33 Antigen,”J. Immunol. 148(4):1149-1154.
Daugherty, B.L. et al. (1991). “Polymerase Chain Reaction Facilitates the Cloning, CDR-Grafting, and Rapid Expression of a Murine Monoclonal Antibody Directed Against the CD18 Component of Leukocyte Integrins,”Nucl. Acids Res. 19(9):2471-2476.
Dean, P.D.G. et al. eds. (1985).Affinity Chromatography: A Practical ApproachIRL Press, Ltd., pp. vii-xiv (Table of Contents Only.).
Dillman, R.O. et al. (Nov. 1, 1988). “Superiority of an Acid-Labile Daunorubicin-Monoclonal Antibody Immunoconjugate Compared to Free Drug,”Cancer Res. 48:6097-6102.
Gennaro, A.R. ed. (2000).Remington: The Science and Practice of Pharmacy20th Edition, Lippincott Williams and Wilkins, pp. xiv-xv (Table of Contents Only.).
Goldenberg, D.M. ed. (1995).Cancer Therapy With Radiolabeled Antibodies, CRC Press: Boca Raton, FL, two pages. (Table of Contents Only.).
Gorman, S.D. et al. (May 1991). “Reshaping a Therapeutic CD4 Antibody,”Proc. Natl. Acad. Sci. USA88:4181-4185.
Houghten, R.A. (Aug. 1985). “General Method for the Rapid Solid-Phase Synthesis of Large Numbers of Peptides: Specificity of Antigen-Antibody Interaction at the Level of Individual Amino Acids,”Proc. Natl. Acad. Sci. USA82(15):5131-5135.
Jones, P.T. et al. (May 29, 1986). “Replacing the Complementarity-Determining Regions in a Human Antibody with Those from a Mouse,”Nature321:522-525.
Kane, S. et al. (Jun. 21, 2002). “A Method to Identify Serine Kinase Substrates,”J. Bio. Chem. 277(25):22115-22118.
Kelley, R. F. et al. (1990). “Folding of Eukaryotic Proteins Produced inEscherichia coli” In Genetic Engineering: Principles and Methods, Setlow, J.K. et al. eds. Plenum Press: New York, NY, vol. 12, pp. 1-19.
Kettleborough, C.A. et al. (1991). “Humanization of a Mouse Monoclonal Antibody by CDR-Grafting: The Importance of Framework Residues on Loop Conformation,”Protein Engineering4(7): 773-783.
Köhler, G. et al. (Aug. 7, 1975). “Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity,”Nature256:495-497.
LoBuglio, A.F. et al. (Jun. 1989). “Mouse/Human Chimeric Monoclonal Antibody in Man: Kinetics and Immune Response,”Proc. Natl. Acad. Sci.USA86:4420-4224.
Lonberg, N. et al. (1995). “Human Antibodies from Transgenic Mice,”Int. Rev. Immunol. 13:65-93.
Lowe, C.R. (1979). “An Introduction to Affinity Chromatography”In Laboratory Techniques in Biochemistry and Molecular Biology, Work, T.S. et al. eds. North-Holland Publishing Company, vol. 7, Part II, pp. 269-273 (Table of Contents Only.).
Maeda, H. et al. (Jul. 1991). “Construction of Reshaped Human Antibodies with HIV-Neutralizing Activity,”Human Antibodies Hybridomas2:124-134.
Mahato, R.I. et al. (1997). “Cationic Lipid-Based Gene Delivery Systems: Pharmaceutical Perspectives,”Pharm. Res. 14(7):853-859.
Mangham, D.C. et al. (1999). “A Novel Immunohistochemical Detection System Using Mirror Image Complementary Antibodies (MICA),”Histopathology35(2):129-133.
Merrifield, R.B. (Jul. 20, 1963). “Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide,”J. Am. Chem. Soc. 85:2149-2154.
Peeters, K. et al. (2001). “Production of Antibodies and Antibody Fragments in Plants,”Vaccine19:2756-2761.
Pollock, D.P. et al. (1999). “Transgenic Milk as a Method for the Production of Recombinant Antibodies,”J. Immunol. Methods231:147-157.
Porath, J. et al. (1975). “Biospecific Affinity Chromatography and Related Methods,” Chapter 2In The Proteins, Third Edition, Neurath, H. et al. eds., Academic Press, Inc., vol. 1, pp. 95-178.
Riechmann, L. et al. (Mar. 24, 1988). “Reshaping Human Antibodies for Therapy,”Nature332:323-327.
Sato, K. et al. (Feb. 15, 1993). “Reshaping a Human Antibody to Inhibit the Interleukin 6-Dependent Tumor Cell Growth,”Cancer Res. 53:851-856.
Schott, H. (1984).Affinity Chromatography: Template Chromatography of Nucleic Acids and Proteins, Marcel Dekker, Inc.: New York, NY, pp. v-vii (Table of Contents Only.).
Shaw, D.R. et al. (Jun. 15, 1987). “Characterization of a Mouse/Human Chimeric Monoclonal Antibody (17-1A) to a Colon Cancer Tumor-Associated Antigen,”J. Immunology138(12):4534-4538.
Shen, W-C. et al. (Oct. 15, 1981). “Cis-Aconityl Spacer Between Daunomycin and Macromolecular Carriers: A Model of pH-Sensitive Linkage Releasing Drug from a Lysosomotropic Conjugate,”Biochem. Biophys. Res. Commun. 102(3):1048-1054.
Stephan, J-P. et al. (1999). “Distribution and Function of the Adhesion Molecule BEN During Rat Development,”Dev. Biol. 212:264-277.
Stephan, J-P. et al. (1999). “Selective Cloning of Cell Surface Proteins Involved in Organ Development: Epithelial Glycoprotein Is Involved in Normal Epithelial Differentiation,”Endocrinology140(12):5841-5854.
Stewart, J.M. et al. (1984).Solid Phase Peptide Synthesis, Second Edition, Pierce Chemical Co.: Rockford, IL, pp. vii-xi (Tabl
Mather Jennie P.
Roberts Penelope E.
Aeder Sean E
Auerbach Jeffrey I.
Edell Shapiro & Finnan LLC
Raven biotechnologies, inc.
LandOfFree
LUCA2 and antibodies that bind thereto does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with LUCA2 and antibodies that bind thereto, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and LUCA2 and antibodies that bind thereto will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4202245